Based on these results, it could be inferred that targeting glucose metabolism in CRC patients bearing KRAS- or BRAF-mutant tumors may be a safer and more effective strategy compared to utterly impairing tumor angiogenesis. This evidence concerns the gene BRAF and colorectal carcinoma.